3 Chronic Therapy Pharma, Glycol Chemical and Household Brand Stocks With a Strong Future Roadmap: Mankind Pharma, India Glycols and Godrej Consumer Products

Mankind Pharma Rs 2,347.60, P/E 47.91. India Glycols Rs 328.55, P/E 7.58. Godrej Consumer Rs 869.40, P/E 46.25. Closing prices of 14 Oct 2026.

Updated: 16 Oct 2026 • 1:27 pm

Posted by:

Quick Answer

Chronic therapy pharma, glycol chemical and household brand stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, India Glycols in glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and Godrej Consumer in household insecticides, soaps and hair colour sold in India, Indonesia and Africa. FY26 revenue growth was 14.8% at Mankind Pharma, 11.5% at India Glycols and 7.9% at Godrej Consumer. P/E stands at 47.91 for Mankind Pharma (industry 37.59), 7.58 for India Glycols (industry 54.53) and 46.25 for Godrej Consumer (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company's risks need equal attention.

Chronic therapy pharma, glycol chemical and household brand stocks give investors exposure to medicines, chemicals and household products used every day. Volumes, pricing and margins decide how much of that demand turns into profit.

Readers comparing chronic therapy pharma, glycol chemical and household brand stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.

This list covers three chronic therapy pharma, glycol chemical and household brand stocks: Mankind Pharma for branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, India Glycols for glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and Godrej Consumer Products for household insecticides, soaps and hair colour sold in India, Indonesia and Africa. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

Table of Contents

What Are Chronic Therapy Pharma, Glycol Chemical and Household Brand Stocks?

Chronic therapy pharma, glycol chemical and household brand stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.

Chronic Therapy Pharma, Glycol Chemical and Household Brand Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three chronic therapy pharma, glycol chemical and household brand stocks as of the 14 Oct 2026 close.

Company	CMP (Rs)	Market Cap (Rs Cr)	P/E	Industry P/E	ROE	Debt to Equity
Mankind Pharma	2,347.60	99,065	47.91	37.59	11.74%	0.39
India Glycols	328.55	2,397	7.58	54.53	9.98%	0.58
Godrej Consumer Products	869.40	88,506	46.25	34.85	14.71%	0.35

Among healthcare, chemicals and consumer stocks, Mankind Pharma and Godrej Consumer trade at a premium to the industry P/E, while India Glycols trades at a discount.

Why Do Chronic Therapy Pharma, Glycol Chemical and Household Brand Stocks Have a Strong Roadmap in India?

Chronic therapy pharma, glycol chemical and household brand stocks have a strong roadmap in India because chronic therapy demand, ethanol and chemical output and household brand spending keep adding volumes for these firms. Three drivers stand out.

Chronic therapies: Doctors prescribe long-course medicines to more patients.
Chemicals and ethanol: Renewable feedstock chemicals and fuel blends find buyers.
Household brands: Insecticides, soaps and hair colour sell across markets.

Mankind Pharma: Branded Formulations Anchor the Roadmap

Mankind Pharma's roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.

Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit was Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.

Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P/E of 47.91 against an industry P/E of 37.59, the stock trades above its industry multiple.

What to watch: Q1 FY27 operating margin was 27.42% against 27.06% for FY26, so margin stability is the figure to follow as volumes grow.

India Glycols: Green Chemicals and Ethanol Build the Next Leg

India Glycols' roadmap rests on glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock, with ethanol blending and chemical demand supporting volumes.

Revenue grew from Rs 2,889.84 crore in FY22 to Rs 4,216.34 crore in FY26, a 45.9% rise, and FY26 revenue was 11.5% higher than FY25. FY26 net profit rose 26.8% to Rs 292.76 crore. In Q1 FY27, revenue grew 19.3% to Rs 2,988.82 crore, and net profit rose 32.2% to Rs 96.83 crore. Operating margin was 7.12% in FY26.

Debt to equity is 0.58 and return on equity is 9.98%. FY26 operating cash flow was Rs 769.16 crore against capital expenditure of Rs 823.48 crore. India Glycols paid a dividend of Rs 7.5 per share for FY26, a yield of 2.10%. At a P/E of 7.58 against an industry P/E of 54.53, the stock trades below its industry multiple.

What to watch: The P/E of 7.58 against an industry P/E of 54.53 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Godrej Consumer Products: Household and Personal Care Brands Drive the Pipeline

Godrej Consumer's roadmap rests on household insecticides, soaps and hair colour sold in India, Indonesia and Africa, with a multi-country brand portfolio supporting sales.

Revenue grew from Rs 12,366.21 crore in FY22 to Rs 15,444.07 crore in FY26, a 24.9% rise, and FY26 revenue was 7.9% higher than FY25. FY26 net profit was Rs 1,861.47 crore. In Q1 FY27, revenue grew 14.2% to Rs 4,277.35 crore, and net profit rose 11.5% to Rs 504.52 crore. Operating margin was 19.45% in FY26.

Debt to equity is 0.35 and return on equity is 14.71%. FY26 operating cash flow was Rs 2,488.47 crore against capital expenditure of Rs 569.53 crore. Godrej Consumer paid a dividend of Rs 20 per share for FY26, a yield of 2.31%. At a P/E of 46.25 against an industry P/E of 34.85, the stock trades above its industry multiple.

What to watch: The P/E of 46.25 sits above the industry P/E of 34.85, so earnings delivery matters for the valuation.

Best Chronic Therapy Pharma, Glycol Chemical and Household Brand Stocks in India: Mankind Pharma vs India Glycols vs Godrej Consumer on Key Financials

Among the best chronic therapy pharma, glycol chemical and household brand stocks in India, Mankind Pharma leads on FY26 revenue growth and FY26 operating margin; India Glycols leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; Godrej Consumer leads on return on equity and the lowest debt to equity. The table puts the numbers side by side.

Metric	Mankind Pharma	India Glycols	Godrej Consumer
FY26 revenue (Rs Cr)	14,636.43	4,216.34	15,444.07
FY26 revenue growth	14.8%	11.5%	7.9%
FY26 net profit (Rs Cr)	1,938.10	292.76	1,861.47
FY26 operating profit margin	27.06%	7.12%	19.45%
Q1 FY27 revenue growth (YoY)	11.7%	19.3%	14.2%
Q1 FY27 net profit growth (YoY)	29.1%	32.2%	11.5%
Return on equity	11.74%	9.98%	14.71%
P/E ratio	47.91	7.58	46.25
Debt to equity	0.39	0.58	0.35
Dividend yield	0.04%	2.10%	2.31%
FY26 operating cash flow (Rs Cr)	3,121.29	769.16	2,488.47

Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Chronic Therapy Pharma, Glycol Chemical and Household Brand Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen chronic therapy pharma, glycol chemical and household brand stocks and shortlist chronic therapy pharma, glycol chemical and household brand stocks to buy.

Compare each stock's P/E with its industry P/E, which differs by company here.
Check revenue growth, operating margin and cash flow together.
Check whether revenue growth is turning into profit growth, not only sales.
Read operating cash flow against capital expenditure to see how growth is funded.
Watch debt to equity and interest cover before sizing a position.
Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these chronic therapy pharma, glycol chemical and household brand stocks

Risks to Consider Before Investing in Chronic Therapy Pharma, Glycol Chemical and Household Brand Stocks

Consumer demand: Spending patterns can shift sales between quarters.
Input costs: Changes in raw material prices can affect margins.
Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Mankind Pharma, India Glycols and Godrej Consumer live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare, chemicals and consumer stocks cover chronic therapy medicines, glycols and household brands. Mankind Pharma leads on FY26 revenue growth and FY26 operating margin; India Glycols leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; Godrej Consumer leads on return on equity and the lowest debt to equity.

Across chronic therapy pharma, glycol chemical and household brand stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the chronic therapy pharma, glycol chemical and household brand stocks to buy discussed here.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Chronic Therapy Pharma, Glycol Chemical and Household Brand Stocks

Which are the best chronic therapy pharma, glycol chemical and household brand stocks in India with a strong roadmap?

Ans. Mankind Pharma, India Glycols and Godrej Consumer Products stand out for their roadmaps in chronic therapy medicines, glycols and household brands. FY26 revenue growth was 14.8% at Mankind Pharma, 11.5% at India Glycols and 7.9% at Godrej Consumer, and return on equity ranges from 9.98% to 14.71%.

Is Mankind Pharma a good stock to buy now?

Ans. Mankind Pharma has a debt to equity ratio of 0.39, a return on equity of 11.74% and a P/E of 47.91 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Mankind Pharma, India Glycols and Godrej Consumer?

Ans. The P/E ratio is 47.91 for Mankind Pharma (industry 37.59), 7.58 for India Glycols (industry 54.53) and 46.25 for Godrej Consumer (industry 34.85). Only Mankind Pharma and Godrej Consumer trade at or above the industry multiple.

Which of these chronic therapy pharma, glycol chemical and household brand stocks has the highest return on equity?

Ans. Godrej Consumer Products has the highest return on equity at 14.71%, followed by Mankind Pharma at 11.74% and India Glycols at 9.98%.

What are the risks of investing in chronic therapy pharma, glycol chemical and household brand stocks?

Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.

How did Mankind Pharma, India Glycols and Godrej Consumer perform in Q1 FY27?

Ans. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. India Glycols reported revenue of Rs 2,988.82 crore, up 19.3% year on year, and net profit rose 32.2% to Rs 96.83 crore. Godrej Consumer Products reported revenue of Rs 4,277.35 crore, up 14.2% year on year, and net profit rose 11.5% to Rs 504.52 crore.

Do chronic therapy pharma, glycol chemical and household brand stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.04% for Mankind Pharma, 2.10% for India Glycols and 2.31% for Godrej Consumer, based on dividends declared for FY26.

How can I invest in chronic therapy pharma, glycol chemical and household brand stocks in India?

Ans. You can buy chronic therapy pharma, glycol chemical and household brand stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.